Skip to content

Belgian Cross-sectional Allogeneic Transplant Survivor Study

Belgian Cross-sectional Allogeneic Transplant Survivor Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02312830
Acronym
BE-C@TS
Enrollment
400
Registered
2014-12-09
Start date
2014-11-30
Completion date
2025-11-30
Last updated
2024-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation, Allogeneic

Brief summary

With the increasing successful use of allogeneic hematopoietic stem cell transplantation (HSCT) to cure advanced hematological disease, it becomes essential to evaluate the long-term effects of such a drastic treatment. This study investigates the prevalence of several demographic, psychosocial and behavioral aspects of survivorship after an allogeneic transplantation. Income, return to work, social isolation, pain, medication adherence, influenza vaccination status, alcohol use, smoking habits, drug use, healthy diet, prevention of UV exposure, physical activity, functional status/Quality of life (QoL), couple life/sexual function, depression, anxiety, spirituality and resilience will be studied.

Detailed description

This is a cross sectional study, where participants are interviewed and fill in a self reported survey. The interview and survey are only taken once. It is non interventional because the patients only give us extra information, which is not usually recorded in our medical records.

Interventions

None listed

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Ability to read and write in Dutch * Age above 18 years at time of transplant * Transplanted in UZ Leuven between 1992 and 2012 with an allogeneic donor (i.e. being at least 2 years post-Tx) * Presenting for a periodic health check in UZLEUVEN from November 15th, 2014 to November 15th 2016 * Willing to provide oral and written consent

Exclusion criteria

* Unable to communicate fluently in Dutch * Presenting with major visual, hearing, cognitive or psychiatric conditions precluding participation * Presenting with relapse or other major illness, with less than 6 months expected survival * Hospitalized for a life-threatening condition

Design outcomes

Primary

MeasureTime frameDescription
composite outcome: prevalence of several demographic, psychosocial and behavioral aspects of survivorship after an allogeneic transplantationThe interview/survey will happen once per patient and will be offered to all transplant survivors (minimum 2 years post transplant) coming to the clinic between Nov 2014-Nov 2016. No follow up included.This is a cross sectional study, assessing several aspects of survivorship with multiple validated questionnaires (EQ5D, PHQ9, GAD, SFQ, etc). These questionnaires are only taken once in all survivors approached for the study.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026